Article in Translational psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03170362 (PRIME Care), which is not on this map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 6 institutions in 1 country.
Zhongshan ChengDivision of Human Genetics, Department of Psychiatry, VA CT Healthcare Center, Yale University School of Medicine, New Haven, CT, USA.
Chureerat PhokaewDivision of Human Genetics, Department of Psychiatry, VA CT Healthcare Center, Yale University School of Medicine, New Haven, CT, USA.
Yi-Ling ChouDepartment of Psychiatry, Washington University School of Medicine, St. Louis, MI, USA.
Dongbing LaiDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
Jacquelyn L MeyersDepartment of Psychiatry, State University of New York Downstate Medical Center, Brooklyn, NY, USA.
Lindsay A FarrerDepartments of Neurology, Ophthalmology, Genetics & Genomics, Epidemiology and Biostatistics, Boston University Schools of Medicine and Public Health, Boston, MA, USA.
Henry R KranzlerDepartment of Psychiatry, Center for Studies of Addiction and Crescenz Veterans Affairs Medical Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-1018-0450
Joel GelernterDivision of Human Genetics, Department of Psychiatry, VA CT Healthcare Center, Yale University School of Medicine, New Haven, CT, USA. joel.gelernter@yale.edu.ORCID http://orcid.org/0000-0002-4067-1859
Yale University · USWashington University in St. Louis · USBoston University · USIndiana University School of MedicineState University of New York · USUniversity of Pennsylvania · US
Funding
Subject CollectionU10AA008401 · NIAAA · SUNY DOWNSTATE MEDICAL CENTER · PI JAY Arnold TISCHFIELD · 1989 to 2026
$162.7M
Sex-specific analysis of opioid dependence GWAS and beyondR01DA012690 · NIDA · YALE UNIVERSITY · PI GELERNTER, JOEL · 2000 to 2017
$14.0M
Linkage Disequilibrium Studies of Alcohol DependenceR01AA011330 · NIAAA · YALE UNIVERSITY · PI GELERNTER, JOEL · 1997 to 2013
$6.4M
Genetics of Alcohol Dependence in African-AmericansR01AA017535 · NIAAA · YALE UNIVERSITY · PI GELERNTER, JOEL · 2009 to 2013
$3.0M
GENOTYPING FOR LOCATING HUMAN DISEASE GENESN01HG065403 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID L · 1996 to 2000
$1.7M
DELINEATING THE ROLE OF GENETIC INFLUENCES ON CANNABIS INVOLVEMENTK02DA032573 · NIDA · WASHINGTON UNIVERSITY · PI AGRAWAL, ARPANA · 2012 to 2021
Cannabis, the most widely used illicit drug, can induce hallucinations. Our understanding of the biology of cannabis-induced hallucinations (Ca-HL) is limited. We used the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA) to identify cannabis-induced hallucinations (Ca-HL) among long-term cannabis users (used cannabis ≥1 year and ≥100 times). A genome-wide association study (GWAS) was conducted by analyzing European Americans (EAs) and African Americans (AAs) in Yale-Penn 1 and 2 cohorts individually, then meta-analyzing the two cohorts within population. In the meta-analysis of Yale-Penn EAs (n = 1917), one genome-wide significant (GWS) signal emerged at the CHRM3 locus, represented by rs115455482 (P = 1.66 × 10
Indexed as
AllelesAnimalsBlack or African AmericanCannabisFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHallucinationsHumansMaleMarijuana AbuseMicePolymorphism, Single NucleotideReceptor, Muscarinic M3White PeopleCHRM3 protein, humanReceptor, Muscarinic M3
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans. · full record | OpenQuestion